![]() Vision Share Spotlights Moria's XTRA4: A Breakthrough in Corneal Preservation and Global ImpactMoria's FDA-cleared XTRA4 introduces a dextran-free storage medium designed to extend corneal preservation and maintain tissue quality during storage.
By: Vision Share "The formulation of XTRA4 reflects a deep understanding of corneal physiology," Developed over years of dedicated research, XTRA4 replaces dextran with a different deswelling agent that better replicates physiological conditions within the cornea. This innovation allows for up to 14 days of storage at 2–8°C, maintaining tissue transparency and endothelial integrity while doubling the traditional preservation window. The FDA's recent 510(k) clearance marks a key milestone for U.S. eye banks and surgeons eager to access extended-life, high-quality tissue. As an advocate for innovation in eye banking, Vision Share is spotlighting the XTRA4 development to advance conversations among clinicians, researchers, and partner eye banks worldwide. The organization continues to highlight technologies and collaborations that improve patient outcomes and expand equitable access to sight-restoring care. The full interview with Moria's team is available on Vision Share's website: visionshare.org About Vision Share Vision Share is a 501(c)(3) nonprofit network of U.S. eye banks committed to advancing global sight restoration. Through its accredited member organizations, Vision Share provides safe, high-quality corneal tissue for transplantation and research, supports innovation in eye banking, and facilitates international collaboration. By connecting surgeons, researchers, and eye banks worldwide, Vision Share works to ensure that access to sight-saving tissue and technologies transcends borders. Learn more at www.visionshare.org. End
|
|